Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists watch brain diseases unfold to find better ways to diagnose and treat

NCT ID NCT02435810

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 8 times

Summary

This study aims to learn more about how infections and inflammation harm the brain and nerves. Researchers will collect samples and perform tests on people aged 2 and older who have or may have these conditions. The goal is to better understand these diseases so that better tests and treatments can be developed in the future. No new treatments are being tested in this study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2015

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will have a known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided.

Ages

2 to 110 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: At the time of enrollment, participants will: 1. Have a known or suspected infection or inflammation of the nervous system or post infection sequelae based on clinical or imaging data provided by the referral facility. For the purpose of this study, neuroinfectious disease or neuroinflammation is defined as any of the following: 1. fever with nervous system signs or symptoms (excluding delirium) 2. any neurological symptoms accompanied by cerebrospinal fluid (CSF) with evidence of inflammation (which may include pleocytosis, hypoglycorrachia, elevated protein, or other evidence of intrathecal immune activation including IgG index or presence of oligoclonal bands) 3. systemic infection or inflammatory disease with neurological involvement 4. neuroimaging suggestive of infection or inflammation (for example, presence of contrast-enhancing lesions on CT or MRI) 5. clinical presentation suggestive of infection or inflammatory process of the nervous system without better explanation 6. history of infection or inflammatory process of the nervous system 2. Be willing to participate in the protocol s procedures, unless clinically contraindicated 3. Be willing to provide informed consent, either directly or via appointed legally authorized representative 4. Be willing to consent for collection of clinical data or biological samples or their cryopreservation 5. Be at least 2 years old INCLUSION CRITERIA FOR PROCESSING OF BIOLOGICAL SAMPLES ONLY: At the time of enrollment, participants will: 1. Have a known or suspected infection or inflammation of the nervous system or post infection sequelae based on clinical or imaging data provided by the referral facility. For the purpose of this study, neuroinfectious disease or neuroinflammation is defined as any of the following: 1. fever with nervous system signs or symptoms (excluding delirium) 2. any neurological symptoms accompanied by cerebrospinal fluid (CSF) with evidence of inflammation (which may include pleocytosis, hypoglycorrachia, elevated protein, or other evidence of intrathecal immune activation including IgG index or presence of oligoclonal bands) 3. systemic infection or inflammatory disease with neurological involvement 4. neuroimaging suggestive of infection or inflammation (for example, presence of contrast-enhancing lesions on CT or MRI) 5. clinical presentation suggestive of infection or inflammatory process of the nervous system without better explanation 6. history of infection or inflammatory process of nervous system 2. Be willing to provide informed consent, either directly or via appointed legally authorized representative 3. Be willing to consent for collection of clinical data or biological samples or their cryopreservation 4. Be at least 2 years old EXCLUSION CRITERIA: At the time of enrollment, participants will: 1. Not have a clinically significant medical condition that, in the best judgment of the investigators, may expose the patient to undue risk of harm or prevent the patient from completing the study (examples include, but are not limited to, ischemic cardiomyopathy, clotting disorder, brittle diabetes) 2. Not have an acute or unstable medical condition that, in the best judgement of the investigator, would be difficult to handle at the NIH Clinical Center 3. Not have a clearly-established diagnosis of well-characterized disease entity with validated treatment algorithms for which proposed resource investment, in the opinion of the investigators, would not contribute to further advancement of knowledge EXCLUSION CRITERIA FOR PROCESSING OF BIOLOGICAL SAMPLES ONLY: At the time of enrollment, participants will not have: 1\. A clearly-established diagnosis of well-characterized disease entity with validated treatment algorithms for which proposed resource investment, in the opinion of the investigators, would not contribute to further advancement of knowledge INCLUSION CRITERIA FOR FAMILY MEMBERS: 1. Have a family member enrolled on 15-N-0125 2. Be at least 2 years old 3. Be able to provide informed consent and comply with study procedures EXCLUSION CRITERIA FOR FAMILY MEMBERS: 1\. Not willing to consent for collection of biological samples or their cryopreservation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.